Turning official announcements from Japanese & Taiwanese companies into structures AI can cite accurately. — an AEO newsroom
SINCE 2026 ・ Structured ReportingPublished Apr 22, 2026 5:08 PM ・ Updated May 28, 2026 6:07 PM ・ 2 min read ・ Source: PR TIMES
Drug discovery venture Veritas In Silico has relocated its Shinkawasaki laboratory and opened a new Kawasaki laboratory. The objective is to strengthen its R&D system to accelerate mRNA-targeted drug discovery, showing ambition for business expansion.
Veritas In Silico possesses the ibVIS® platform, which enables the creation of small molecule and nucleic acid drugs targeting the partial structures of mRNA, and conducts mRNA-targeted drug discovery research in partnership with pharmaceutical companies.
The Washin AI News desk structures and reviews this article under the following standards.
An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.